CCMCL1: a new model of aggressive mantle cell lymphoma

Blood. 2015 Apr 23;125(17):2730-2. doi: 10.1182/blood-2015-01-622795.

Authors

Affiliations

¹ Department of Laboratory Medicine, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH.
² Department of Pathology and Laboratory Medicine, Sandra and Edward Meyer Cancer Center, Weill Cornell Medical College, New York, NY.
³ Department of Physiology and Biophysics, Institute for Computational Biomedicine, Weill Cornell Medical College, New York, NY.
⁴ Department of Hematologic and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adenine / analogs & derivatives
Animals
Antibodies, Monoclonal, Murine-Derived / administration & dosage
Antibodies, Monoclonal, Murine-Derived / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Boronic Acids / administration & dosage
Boronic Acids / therapeutic use
Bortezomib
Cell Line, Tumor
Humans
Lymphoma, Mantle-Cell / drug therapy
Lymphoma, Mantle-Cell / genetics
Lymphoma, Mantle-Cell / pathology*
Male
Mice
Mice, Inbred NOD
Mice, SCID
Middle Aged
Neoplasm Transplantation
Neoplasms, Experimental
Piperidines
Pyrazines / administration & dosage
Pyrazines / therapeutic use
Pyrazoles / administration & dosage
Pyrazoles / therapeutic use
Pyrimidines / administration & dosage
Pyrimidines / therapeutic use
Rituximab
Tumor Cells, Cultured

Substances

Antibodies, Monoclonal, Murine-Derived
Boronic Acids
Piperidines
Pyrazines
Pyrazoles
Pyrimidines
ibrutinib
Rituximab
Bortezomib
Adenine